Dynavax (DVAX) Reports Q3 Loss of $0.24/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Dynavax Technologies (DVAX) PT Raised to $30 at Cowen
November 5, 2021 6:45 AM EDTCowen analyst Phil Nadeau raised the price target on Dynavax Technologies (NASDAQ: DVAX) to $30.00 (from $20.00) while maintaining an Outperform rating.
The analyst commented, "DVAX reported Q3 Heplisav rev. of $22.7MM, above consensus ($15MM) as share at targeted accounts increased to... More
